Irritable Bowel Syndrome is caused by virus or Bacteria present in the Intestines
Irritable bowel syndrome is a digestive system illness that causes stomach pain and changes in bowel habits. It obstructs the normal mobility of intestinal muscular linings, which is necessary for food to flow through the digestive tract. Irritable bowel syndrome is classified as mild, moderate, or severe depending on the symptoms. Cramps, abdominal pain, bloating and gas, mucus in the stool, constipation, and diarrhoea are some of the symptoms. Irritable bowel syndrome has no established aetiology, however it has been linked to increased awareness of body functions and irregular gastrointestinal tract motions.
The global Irritable
Bowel Syndrome Treatment Market was valued at US$ 726.1 million in
2016 and is expected to witness a robust CAGR of 12.9% over the forecast period
(2017-2025). Tests such as blood tests, stool tests, endoscopic procedures, and
external imaging procedures are used to diagnose irritable bowel syndrome.
Irritable bowel syndrome patients may develop consequences such as severe
ulcerations, infections, malnutrition, and intestinal blockages. Irritable
bowel syndrome treatment aims to alleviate symptoms and improve the patient's
quality of life.
Irritable Bowel Syndrome Treatment |
In other words, Irritable bowel syndrome (IBS) affects the large intestine and is a prevalent condition. Cramping, abdominal pain, bloating, gas, and diarrhoea or constipation, or both, are signs and symptoms. IBS is a long-term condition that you'll have to deal with. Only a small percentage of IBS patients experience severe indications and symptoms. Diet, lifestyle, and stress management can help some people manage their symptoms. Medication and counselling can help with more severe symptoms. IBS does not result in intestinal tissue alterations or an increased risk of colorectal cancer.
Over the last few years, the number of irritable bowel
syndrome medications accessible has expanded, and new drugs have been licenced
for the treatment. The global Irritable
Bowel syndrome Treatment market is dominated by North America,
followed by Europe and Asia-Pacific, respectively. According to a 2017 study
published in the Brandon Gaille, junk food accounts for 28.8% of an American's
overall caloric intake on average. In 2015, the Centers for Disease Control and
Prevention (CDC) projected that 1.3 percent of adults in the United States, or
3 million people, had been diagnosed with IBD.
Consumption of unhealthy foods in big numbers boosts the
likelihood of IBS acting as a growth driver for the global market. In addition,
the firms are involved in the development, distribution, and marketing of
irritable bowel syndrome treatment medications in certain countries such as
Japan and China, which is projected to drive the Asia-Pacific irritable bowel
syndrome treatment market forward. Sucampo Pharmaceutical, Inc., for example,
worked with Herbin Gloria Pharmaceuticals in 2015 to sell its medicine in
China.
Females are more likely than guys to suffer from irritable
bowel syndrome. IBS affects two out of every three women, according to the
International Foundation for Functional Gastrointestinal Disorders. Lotronex
(Alosetron), Amitiza (Lubiprostone), Linzess (Linclotide), and Xifaxan are some
of the U.S. Food and Drug Administration-approved medications for treating IBS
symptoms (Rifaximin).
Comments
Post a Comment